120-OR: Efficacy of Tirzepatide in Achieving the Composite Endpoints of Glycemic, Blood Pressure, and Lipid Goals in SURMOUNT-2

In the SURMOUNT-2 (SM-2) trial of adults with overweight/obesity and type 2 diabetes (T2D), tirzepatide (TZP), a once weekly GIP/GLP-1 receptor agonist, significantly reduced body weight (BW) in conjunction with a reduced calorie diet and increased physical activity. This post-hoc analysis assessed...

Full description

Saved in:
Bibliographic Details
Published inDiabetes (New York, N.Y.) Vol. 73; p. 1
Main Authors Sattar, Naveed, Cheng, Alice YY, Benabbad, Imane, Lee, Clare, See, Sophia Kyoungah, Leech, John, Mojdami, Donna
Format Journal Article
LanguageEnglish
Published New York American Diabetes Association 01.06.2024
Subjects
Antidiabetics
Blood pressure
Body weight
Body weight loss
Diabetes mellitus (non-insulin dependent)
High density lipoprotein
Lipids
Obesity
Overweight
Physical activity
Weight control
Online AccessGet full text

Cover

More Information
Summary:In the SURMOUNT-2 (SM-2) trial of adults with overweight/obesity and type 2 diabetes (T2D), tirzepatide (TZP), a once weekly GIP/GLP-1 receptor agonist, significantly reduced body weight (BW) in conjunction with a reduced calorie diet and increased physical activity. This post-hoc analysis assessed the proportion of participants achieving composite endpoints of BP <130/80 mm Hg, non-HDL <130 mg/dl, and three HbA1c thresholds of <7%, < 6.5% and <5.7% at 72 weeks. Logistic regression with missing value imputed by mixed model repeated measures, using the efficacy estimand, assessed participants who achieved the composite endpoints, in the 10mg (N=312) or 15mg (N=311) TZP groups, versus placebo (PBO) (N=315). Overall baseline mean BW was 100.7 kg, BMI 36.1kg/m2, HbA1c 8.02%, BP 130.5/79.8 mm Hg and non-HDL 132.5 mg/dl. For 15mg TZP, 33.8%, 32.8%, and 25.9% of participants achieved the composite endpoints versus 7.5%, 3.9%, and 0.7% of PBO at 72 weeks (Fig). Findings for the TZP 10mg group were similar to those observed in the 15mg group. In people with T2D and overweight/obesity, higher proportion of participants receiving TZP achieved clinically meaningful composite endpoints, which included BP, lipids and HbA1c goals compared to PBO. This suggests that TZP can help achieve multiple clinical goals, in addition to meaningful weight loss, important for improving cardiometabolic health.
ISSN:0012-1797
1939-327X
DOI:10.2337/db24-120-OR